Combined raman spectroscopy-optical coherence tomography (RS-OCT) system and application of the same
Patent Numbers: US7508524 and US8553219
Executive Summary:
General Description:
Skin cancer is the most common cancer with over 1.7 incidences in the US per year. However, they are highly curable when detected in an early state. The current gold standard for skin cancer detection is invasive, time-consuming, costly and can be subjective.
The current invention describes a device that can distinguish malignant skin lesions from normal skin lesions without the need for biopsy. By combining optical techniques with spectroscopic techniques, this device is capable of directly analyzing potential cancerous skin lesions.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Anita Mahadevan-Jansen
https://engineering.vanderbilt.edu/bio/anita-mahadevan-jansen
Executive Summary:
- Invention Type: Diagnostic and Device
- Patent Status: Active
- Patent Links: https://patents.google.com/patent/US7508524/, https://patents.google.com/patent/US8553219/
- Research Institute: Vanderbilt University
- Disease Focus: Melanoma
- Basis of Invention: Evaluation of normal and cancerous skin lesions
- How it works: The invention combines Raman spectroscopy with optical coherence tomography for non-invasive diagnosis of skin lesions. Raman spectroscopy is an optical technique that can be used to determine the biochemical composition of human tissue. These biochemical data are linked with tissue structure data by using optical coherence tomography, which is an imaging technique producing tissue microstructure with near histological resolution
- Lead Challenge Inventor: Anita Mahadevan-Jansen
- Inventors: Anita Mahadevan-Jansen, Ton Van Leeuwen, Chetan A. Patil
- Development Stage: Pre-clinical (human sample data)
- Novelty:
- Golden standard for skin cancer diagnosis involves biopsy. Current invention provides non-invasive, efficient way to diagnose skin cancers
- Clinical Applications:
- Device to distinguish benign from malignant skin lesions
General Description:
Skin cancer is the most common cancer with over 1.7 incidences in the US per year. However, they are highly curable when detected in an early state. The current gold standard for skin cancer detection is invasive, time-consuming, costly and can be subjective.
The current invention describes a device that can distinguish malignant skin lesions from normal skin lesions without the need for biopsy. By combining optical techniques with spectroscopic techniques, this device is capable of directly analyzing potential cancerous skin lesions.
Strengths:
- Non-invasive
- Cost-efficient
- Less time consuming than current diagnostics
- Objective
Weaknesses:
- Efficient ways for diagnosis of skin cancer already available
Patent Status:
- Filing dates: 2007-07-20 and 2011-01-24
Inventor Bio: Anita Mahadevan-Jansen
https://engineering.vanderbilt.edu/bio/anita-mahadevan-jansen
